drfeelgood

Dr. Selcuk Seber
Medical Oncologist
Tekirdag Namık Kemal University
time spender,IO, performing precision oncology in a low resource enviorment

[drfeelgood @drfeelgood049]

https://t.co/YZrQgip0zp Ki-67 as a treatment decision modifier in breast cancer. The Oncologist, Volume 31, Issue 7, July 2026, oyag183 #Ki67 #breastcancer

[Mustafa SARI, Prof. Dr. @profmustafasari]

MUTLUYUZ!

Çünkü Tekirdağ'dan başlayan Marmara Denizi turumuz devam ediyor. Çanakkale Boğazı hariç bütün istasyonlarda bebek pinalar çoğalıyor.

Çünkü hemen hemen bütün istasyonlarda deniz çayırları sağlıklı. Çayırların maksimum derinlikleri artıyor ve sınırların çoğu "ilerleyen" formda.

Çünkü hiç bir istasyonda "şimdilik" müsilaj yok.

Çünkü her yerde yavru balıklar var. Mevcut balık popülasyonlarında üreme devam ediyor.

Bu gönderide mutsuz hiç bir bilgiye yer vermeyeceğim. Bütün istasyonlar bittiğinde mutsuz olduklarımı, başka bir gönderi de riskleri ve beklentilerimi yazacağım.

Var ol Umut Pina!
Çok yaşa, hep yaşa!
Ömrün uzun olsun!
Kabuğuna müsilaj, kaçak ağ, çapa, deniz dolgusu değmesin!

Fotoğraf Mudanya'da @ugurkaradurmus hoca tarafından çekildi. Teşekkürler @KaradurmusUgur @azotdalismerkezi @eslemkurrt @alib10.5 @fealtunsoy @umutpina @pinaelcileri

[Edwin Drake @petrolandeco]

Spin-off denen şey bu işte.
Ama sorun, özel sektörün bir türlü bu harekete tam olarak katılmaması. Daha doğrusu potansiyelinin çok altında bir performans.

Türkiye’nin ilk yerli kalp-akciğer makinesi ASELSAN LIFELINE HLM, ilk defa bir kalp ameliyatında görev aldı.
Dünyada bunu yerli tasarım ve üretim yapabilen 8-9 ülke var.
ABD, Almanya, İtalya, İngiltere, İsveç, Japonya, Brezilya, Çin.

Tekrar edelim.
Herşeyi yaparak gidebilecek yolumuz kalmadı.
Bugün Çin, yarın Hindistan.
Artık imalat sanayi daha niş, daha kalibre alanlara yönelmeli.
Bu bir tercih değil.
Mecburiyet.
Sivil - ticari sanayi gücünün önünde bir savunma sanayi tecrübe ve bilgi birikimi var..

[Stephen V Liu, MD @StephenVLiu]

Carboplatin + etoposide + durvalumab for EGFR mutant NSCLC transformed to SCLC (cohort in ORCHARD study) showed RR 43%, mDOR 4.3m, mPFS 4.2m, mOS 10.2m. Unclear contribution of immunotherapy in this setting - no clear standard (chemo-IO vs chemo-TKI).

https://t.co/hdkKoHOLGy

[Stephen V Liu, MD @StephenVLiu]

Value of immunotherapy is the long tail to the OS curve, but what about the other side of the KM? Report of CheckMate 227 (NSCLC) @CCR_AACR noted rapid progression with 1L nivo/ipi in 40% (vs 26% with chemo). Associated with high neutrophil:leukocyte ratio, low TMB, PDL1 0%, low albumin, higher-than-median baseline monocytic myeloid-derived suppressor cell (M-MDSC). Increased early detriment not seen with nivo/ipi plus chemo (CheckMate 9LA).

https://t.co/VAb19CwY5n

[Conflict @ConflictTR]

ASELSAN’ın tamamen yerli imkânlarla geliştirdiği Türkiye’nin ilk yerli kalp-akciğer makinesi LIFELINE HLM kullanılarak ilk açık kalp ameliyatı başarıyla gerçekleştirildi.

[Rohit Malde @roxboxfix]

Uterine Leiomyosarcoma

RT alone Vs Chemo alone Vs CTRT

Decades old debate
No RCT yet

3 centre ( Multicentre Retrospecitive cohort study)

2010-2019

PFS & OS

Stage wise
Modality wise

Agree its Retrospective at the end of the day and best evidence as of now.
ChemoRadiation

[Tıbbiyeli Sözlük @tibbiyelisozluk]

Bu öyle bir olay ki devletin üstün hizmet madalyası hazırlatması,bakanlığının da bizzat Malatya'ya gidip takdim etmesi gerekiyor..
Dünya'da ilk ya hani..

[Elisa Agostinetto @ElisaAgostinett]

One of my favorite abstracts of this #ASCO26 - reduced denosumab dose intensity (q12w) is NON inferior to q4w in pts with mBC or mCRPC, with improved safety profile in terms of risk of hypocalcemia and osteonecrosis of the jaw

Practice changing!!

@OncoAlert

[Rebecca Shatsky, MD @Dr_RShatsky]

This is one of my favorite abstracts from the rapid orals. Sleep issues are HUGE for breast cancer patients on endocrine therapy. The fact that #elizanetant helps both hot flashes AND sleep is really impressive. #ASCO2026

[MV Chandrakanth @ChandrakanthMv]

CDK4/6 inhibitors changed HR+ breast cancer.

But ER-low disease may tell a different story.

A small ASCO 2026 registry analysis suggests substantially shorter PFS and OS despite CDK4/6 inhibitor therapy.

Important signal. Not practice-changing yet.

Bao et al. #ASCO2026 #BreastCancer #MVOnco

[Harold J. Burstein, MD, PhD, FASCO @DrHBurstein]

Important to note two things:
1) this was ''non-invasive breast neoplasia,' (ie DCIS or hyperplasia) not breast cancer.
2) low-dose tamoxifen had no effect in premenopausal women, arguably the group most interested in this approach.
Caution warranted in cancer patients.

[Yakup Ergün @dr_yakupergun]

If we could bring more oncology drugs discovered in China to the global market, access to cancer treatment might become more equitable.

Earlier Chinese trials did have important limitations, no doubt. But given the level of innovation and trial quality in recent years, I think they are now being judged too harshly.

China (Asia) has become a major center of oncology innovation.

And , at a lower cost.

[Elvina Almuradova @Dr_ElvinaA]

Less is more!!!

#ASCO26, low-dose tamoxifen (5 mg/day) delivered durable protection against breast cancer events in women with DCIS and high-risk lesions, with minimal serious toxicity.

A compelling case for endocrine therapy de-escalation. #BreastCancer @larvol @OncoAlert @mirrorsmed

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

TDXd + Durva shows improved activity in immune-enriched HER2+ MBC in DESTINY-Breast07 @LoiSher @OncoAlert #ASCO26

[Paolo Tarantino @PTarantinoMD]

The OPTIMA trial addresses a huge unmet need, and the data, although with short follow up, are striking. Premenopausal patients with N+ tumors and PAM50 ROR<60 do not appear to benefit from chemo, in the setting of adequate OFS. A step forward toward sparing unnecessary chemo.

[Yakup Ergün @dr_yakupergun]

#ASCO26

Does CDK4/6i really work in ER-low disease?

I had also really wanted to study the efficacy of CDK4/6 inhibitors in ER-low tumors, but I could not collect enough data. This study addresses exactly this important question. First of all, congratulations to the investigators.

In ER-low HR+/HER2− MBC, CDK4/6i + ET does not seem to deliver the expected HR+ benefit: PFS was 2.9 months. In ER-high patients, PFS was 23.3 months.

Despite the small sample size and the inherent limitations of a retrospective study, the observed behavior is consistent with what we would expect from ER-low tumors. ER-low disease should not simply be placed into the classic HR+ category with automatic CDK4/6i + ET. This subtype behaves closer to TNBC.

[Dr Sarah Sammons @drsarahsam]

ALND indications in 2026 per Boughey at #ASCO26
1) IBC
2) 3+ positive SLNs
3) cN2a/cN3 upfront and after NAC, persistent nodal disease or matted nodes at presentation.
4) SLN+ (ypN+) still pending A11202 and TAXIS.

[Allison Fitzgerald, MD, PhD @allisonoconn]

Today I learned pneumonitis caused by T-Dxd usually occurs around month 4-5 of treatment for breast cancer patients, but earlier (~2 mo) for pts w/ lung and gastric tumors. Patients need a CT chest every 6-12 weeks to monitor for ILD for the first several months of tx